Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2024-A01559-38 | Registry Identifier | RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital, Lille | OTHER |
| Groupe Hospitalier Pitie-Salpetriere | OTHER |
Not provided
Not provided
Not provided
Not provided
Many neurological disorders show a strong genetic basis, from hereditary diseases caused by a single mutation in a given gene, to diseases caused by combinations of strong genetic risk factors. However, even after the sequencing of the appropriate genes, a large proportion of patients remains undiagnosed, either because there is no candidate mutation observed, or in case of identification of a candidate mutation with insufficient knowledge to consider it as pathogenic or not.
The aim of this project is to identify the cause of neurogenetic diseases in patients in situations of diagnostic wandering or dead ends by proposing the analysis of RNA and/or proteins from different tissues.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Controls | Other |
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RNA and/or DNA methylation and/or protein analysis | Genetic | RNA and/or DNA methylation and/or protein analysis from a blood sample or another tissue including dedifferenciation into induced pluripotent stem cells |
| Measure | Description | Time Frame |
|---|---|---|
| number and proportion of patients | number and proportion of patients in the "Patients with inconclusive results" group for whom a final diagnosis can be made at the end of this research. | through study completion, an average of 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Inclusion | Inclusion of at least 50 participants with successful implementation of at least two procedures (see below, list of procedures) | through study completion, an average of 5 years |
| Identification of at least one candidate biomarker linked to one or more abnormalities of a gene or group of genes. |
Not provided
Inclusion Criteria:
For this project, the inclusion of 3 participant profiles is required:
For all 3 groups:
Exclusion Criteria:
For patients with inconclusive results: Patient with a neurological disease not suspected of a monogenic or oligogenic cause
For healthy relatives: existence of a neurological disease (other than uncomplicated migraine) or psychiatric disease (other than simple anxiety stable under treatment).
-
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gaƫl Nicolas, MD, PhD | Contact | 0033232888747 | gael.nicolas@chu-rouen.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rouen University Hospital | Recruiting | Rouen | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002493 | Central Nervous System Diseases |
| ID | Term |
|---|---|
| D009422 | Nervous System Diseases |
Not provided
Not provided
Qualification: Category 2 Product or procedure: excluding health products (products not mentioned in Article L.5311-11 of the Public Health Code)
Not provided
Not provided
Not provided
Not provided
Identification of at least one candidate biomarker linked to one or more abnormalities of a gene or group of genes. |
| through study completion, an average of 5 years |